Editing AUA: Female SUI (2023) (section)

====== Bulking agents ======
* Trade name: Bulkamid
**FDA approved in 2020[https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170023B.pdf §]
*'''Little long-term data'''
* '''<span style="color:#ff0000">Indications (2):</span>'''
*#'''<span style="color:#ff0000">Patients who wish to avoid more invasive surgical management or are concerned with the lengthier recovery time after surgery</span>''' 
*#'''<span style="color:#ff0000">Patients who experience insufficient improvement following a previous anti-incontinence procedure.</span>'''
*'''<span style="color:#ff0000">Disadvantage (1)</span>'''
*#'''<span style="color:#ff0000">Patients should be counseled on the expected need for repeat injections</span>'''
*Adverse events[https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170023C.pdf §]
**Pain at implantation (13%)
**Acute urinary retention (6%)
**Urinary tract infection (4%)
**Blood in urine (2%)